MetaCap

Aligos Therapeutics (ALGS) vs TScan Therapeutics (TCRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TScan Therapeutics (TCRX) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 84.8% versus a loss of 86.8%. Over five years, TCRX leads with a -98.3% price change compared with -99.7% for ALGS. TScan Therapeutics is the larger company by market cap ($9.9 million vs $7.6 million), about 1.3 times the size.

Aligos Therapeutics converts more of its revenue into profit, with a net margin of -1106.7% versus -1256.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALGS-86.75%TCRX-84.85%
+55%-19%-94%
Nov 21, 20251 yearNov 20, 2026
ALGS-99.69%TCRX-98.34%
+7%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALGS versus TCRX key metrics
MetricALGSTCRX
Share price$1.22$0.1459
Market cap$7.62M$9.89M
1-day change-2.40%+2.24%
YTD return-86.91%-85.41%
1-year return-86.75%-84.85%
5-year return-99.70%-98.33%
EPS (TTM)$-6.46$-0.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.19M$10.32M
Revenue growth (YoY)-39.46%+266.65%
Net income (latest FY)$-24.19M$-129.77M
Operating margin-4024.93%-1315.38%
Net margin-1106.72%-1256.81%
52-week high$13.69$1.47
52-week low$1.18$0.14
Distance from 52-week high-91.09%-90.07%
Analyst consensusnonehold
Avg. price target upside+4193.44%+585.40%
Average volume57.37K766.11K
Shares outstanding5.45M63.50M
Employees82138
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Aligos Therapeutics is more profitable, keeping -1106.7 cents of every revenue dollar as net income versus -1256.8 cents for TScan Therapeutics.
  • TScan Therapeutics grew revenue faster in its latest fiscal year (+266.65% vs -39.46%).

About Aligos Therapeutics

ALGS stock →

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees

About TScan Therapeutics

TCRX stock →

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees

ALGS vs TCRX FAQ

Which is bigger, Aligos Therapeutics or TScan Therapeutics?

TScan Therapeutics (TCRX) is larger, with a market capitalization of $9.89M compared with $7.62M for Aligos Therapeutics (ALGS).

Which stock has performed better over the past year, ALGS or TCRX?

TCRX returned -84.85% over the past 12 months, compared with -86.75% for ALGS (price return, excluding dividends). Past performance does not predict future results.

Are Aligos Therapeutics and TScan Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons